|
|
Unicycive Therapeutics Inc (NASDAQ: UNCY) |
|
*Market share is calculated based on total revenue.
News about Unicycive Therapeutics Inc Contracts |
September 3, 2024
Unicycive Therapeutics Announces NDA Submission to U.S. FDA for Innovative Phosphate Binder Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company dedicated to the development of therapies for kidney disease, has recently made an important stride in its mission to improve the lives of patients suffering from chronic kidney disease (CKD). On September 3rd, 2024, the company announced that it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC), a novel phosphate binder aimed at managing hyperphosphatemia in CKD patients on dialysis. Hyperphosphatemia, an elevated level of phosphate in the blood, is a common and ...
|
July 10, 2024
Unicycive Therapeutics, a clinical-stage biotechnology company, has recently released positive patient satisfaction findings from a pivotal clinical trial of Oxylanthanum Carbonate (OLC). Patients participating in the trial expressed a strong preference for OLC over their prior phosphate binder therapy. Additionally, the company has presented data demonstrating the bioequivalence of OLC to Lanthanum Carbonate, further supporting the potential of this new therapy. Multiple presentations featuring OLC and another product candidate, UNI-494, will be delivered at the upcoming European Renal Association Congress, highlighting the significant progress in the field of kidney disease treatment.Patient Satisfaction w...
|
December 18, 2023
Unicycive Therapeutics, a leading biopharmaceutical company, recently announced a significant step forward in the treatment of Chronic Kidney Disease (CKD) on dialysis. By enrolling the first patient in a pivotal clinical trial for Oxylanthanum Carbonate (OLC), Unicycive aims to potentially revolutionize the management of CKD, providing hope for millions of affected individuals. With the study evaluating a cohort of 60 participants, the results are eagerly anticipated in the second quarter of 2024.
Unprecedented Potential for Revolutionary Treatment:
CKD is a chronic, progressive condition affecting the kidneys filtration ability, leading to the accumulation of toxins and waste in the body...
|
Publicly Traded Peers of Unicycive Therapeutics Inc
Acadia Pharmaceuticals Inc
Share Performance
+15.47%
This Year
|
Acadia Pharmaceuticals Inc
Profile
Acadia Pharmaceuticals Inc's business model centers around the research, development, and commercialization of innovative medicines for diseases related to the central nervous system. They collaborate with a network of partners and employ a combination of in-house research and licensing agreements to discover and develop drug candidates. Their primary revenue stream comes from the sales of approved products, with a focus on providing effective therapeutic options for patients with unmet medical needs.
More about Acadia Pharmaceuticals Inc 's Market Share
|
Ac Immune Sa
Share Performance
+36.84%
This Quarter
|
Ac Immune Sa
Profile
Ac Immune Sa is a biopharmaceutical company that focuses on developing precision medicine to target neurological and neurodegenerative diseases. Their business model revolves around leveraging their proprietary technology platforms and partnerships with pharmaceutical companies to advance their drug discovery and development programs. Through licensing agreements and collaborations, they aim to bring innovative therapeutics to the market that address the urgent unmet needs in the field of neurology.
More about Ac Immune Sa's Market Share
|
Alterity Therapeutics Limited
Share Performance
0.00%
Over The Past 5 Days
|
Alterity Therapeutics Limited
Profile
Alterity Therapeutics Limited's business model focuses on the development of innovative therapies to treat neurodegenerative diseases, with a special emphasis on Parkinson's disease and Alzheimer's disease.
More about Alterity Therapeutics Limited's Market Share
|
Cerevel Therapeutics Holdings Inc
Share Performance
+6.52%
This Year
|
Cerevel Therapeutics Holdings Inc
Profile
Cerevel Therapeutics Holdings Inc operates as a biopharmaceutical company that focuses on developing and commercializing therapies for central nervous system disorders. Their business model revolves around innovative research and development to discover new treatments, strategic partnerships for financing and distribution, and ultimately bringing these therapies to market to improve the lives of patients with neurological conditions. They aim to address unmet medical needs in the field of neurology through their targeted drug development approach.
More about Cerevel Therapeutics Holdings Inc 's Market Share
|
Lipocine Inc
Share Performance
0.00%
Over The Past 5 Days
|
Lipocine Inc
Profile
Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.
More about Lipocine Inc 's Market Share
|
Promis Neurosciences inc
Share Performance
-24.60%
30 Days
|
Promis Neurosciences inc
Profile
Promis Neurosciences Inc is a biotech company focused on developing innovative therapies for neurodegenerative diseases like Alzheimer's and ALS. Their business model revolves around leveraging their expertise in neurosciences to discover and develop novel drug candidates that target protein misfolding, a key driver of these diseases. By translating their research into potential therapies, Promis Neurosciences aims to address unmet medical needs and improve the lives of patients suffering from neurodegenerative disorders.
More about Promis Neurosciences inc 's Market Share
|
Sage Therapeutics Inc
Share Performance
+59.17%
This Year
|
Sage Therapeutics Inc
Profile
Sage Therapeutics Inc's business model primarily revolves around researching, developing, and commercializing innovative therapies for various central nervous system disorders. The company focuses on discovering novel molecules and applying them to create targeted treatments that address the unmet medical needs of patients. By harnessing scientific advancements and strategic collaborations, Sage aims to deliver transformative therapies for individuals suffering from conditions such as depression, postpartum depression, and other mood disorders.
More about Sage Therapeutics Inc 's Market Share
|
Synaptogenix Inc
Share Performance
+89.16%
One Year
|
Synaptogenix Inc
Profile
Synaptogenix Inc is a biotechnology company focused on developing innovative therapeutics for the treatment of neurodegenerative diseases. Their business model revolves around conducting research and clinical trials to identify and develop novel drugs that target the underlying mechanisms of these diseases. By collaborating with academic institutions and utilizing their expertise, the company aims to eventually commercialize their drug candidates for the benefit of patients worldwide.
More about Synaptogenix Inc 's Market Share
|
Akebia Therapeutics Inc
Share Performance
+110.00%
This Year
|
Akebia Therapeutics Inc
Profile
Akebia Therapeutics Inc's business model revolves around the development and commercialization of innovative therapies for kidney disease.
More about Akebia Therapeutics Inc 's Market Share
|
Allarity Therapeutics Inc
Share Performance
-5.41%
This Year
|
Allarity Therapeutics Inc
Profile
Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.
More about Allarity Therapeutics Inc 's Market Share
|
Amgen Inc
Share Performance
+1.72%
This Quarter
|
Amgen Inc
Profile
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
More about Amgen Inc 's Market Share
|
Astrazeneca Plc
Share Performance
-8.91%
One Year
|
Astrazeneca Plc
Profile
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
More about Astrazeneca Plc's Market Share
|
Biophytis Sa
Share Performance
-56.72%
This Quarter
|
Biophytis Sa
Profile
Biophytis SA is a biotechnology company that focuses on developing innovative therapeutics for age-related diseases, with a specific emphasis on degenerative eye diseases and muscle wasting conditions. They leverage their expertise in biology and clinical development to discover and advance targeted drug candidates, aiming to address the unmet medical needs of patients in these areas.
More about Biophytis Sa's Market Share
|
Casi Pharmaceuticals inc
Share Performance
-78.37%
One Year
|
Casi Pharmaceuticals inc
Profile
Casi Pharmaceuticals Inc. operates under a business model that focuses on the development and commercialization of innovative pharmaceutical products. They likely employ a combination of in-house research and development, partnerships, and licensing agreements to bring their products to market. The company may also engage in strategic marketing and distribution partnerships to ensure the successful commercialization of their therapeutics.
More about Casi Pharmaceuticals inc 's Market Share
|
Corcept Therapeutics Inc
Share Performance
+5.13%
This Quarter
|
Corcept Therapeutics Inc
Profile
Corcept Therapeutics Inc operates using a business model that focuses primarily on the research, development, and commercialization of pharmaceutical products. The company aims to discover and develop medications for conditions related to cortisol dysregulation, with a specific focus on Cushing's syndrome and psychiatric disorders. Additionally, Corcept Therapeutics Inc aims to ensure the successful commercialization of their products through collaborations and partnerships with other organizations to reach a wider market.
More about Corcept Therapeutics Inc's Market Share
|
Crinetics Pharmaceuticals Inc
Share Performance
0.00%
Over The Past 5 Days
|
Crinetics Pharmaceuticals Inc
Profile
Crinetics Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. They primarily generate revenue through the sale of their developed drugs and potential partnerships with other pharmaceutical companies.
More about Crinetics Pharmaceuticals Inc 's Market Share
|
Gilead Sciences Inc
Share Performance
+8.38%
This Quarter
|
Gilead Sciences Inc
Profile
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
More about Gilead Sciences Inc 's Market Share
|
Immuron Limited
Share Performance
-0.01%
30 Days
|
Immuron Limited
Profile
Immuron Limited's business model involves the development and commercialization of oral immunotherapeutics that target and treat various diseases.
More about Immuron Limited's Market Share
|
Iterum Therapeutics Plc
Share Performance
+6.00%
30 Days
|
Iterum Therapeutics Plc
Profile
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
More about Iterum Therapeutics Plc's Market Share
|
Johnson and Johnson
Share Performance
+2.62%
This Quarter
|
Johnson and Johnson
Profile
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
More about Johnson and Johnson's Market Share
|
Eli Lilly And Company
Share Performance
+4.41%
This Quarter
|
Eli Lilly And Company
Profile
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
More about Eli Lilly And Company's Market Share
|
Mannkind Corporation
Share Performance
-30.92%
One Year
|
Mannkind Corporation
Profile
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
More about Mannkind Corporation's Market Share
|
Medicinova Inc
Share Performance
-9.29%
This Quarter
|
Medicinova Inc
Profile
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
More about Medicinova Inc 's Market Share
|
Merck and Co Inc
Share Performance
0.00%
Over The Past 5 Days
|
Merck and Co Inc
Profile
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
More about Merck and Co Inc 's Market Share
|
Myovant Sciences Ltd
Share Performance
+0.19%
This Year
|
Myovant Sciences Ltd
Profile
Myovant Sciences Ltd operates under a biopharmaceutical business model primarily focused on the development and commercialization of therapies for women's health and prostate cancer. The company aims to leverage its expertise in clinical research, regulatory affairs, and manufacturing to bring innovative treatments to market and improve patients' lives. Myovant Sciences employs a combination of in-house research and development along with collaboration with strategic partners to advance its pipeline of product candidates.
More about Myovant Sciences Ltd 's Market Share
|
Novartis Ag
Share Performance
+26.56%
This Year
|
Novartis Ag
Profile
Novartis AG's business model is centered around the development, manufacturing, and marketing of innovative pharmaceutical products.
More about Novartis Ag's Market Share
|
Organon and Co
Share Performance
-51.94%
One Year
|
Organon and Co
Profile
Organon and Co's business model revolves around developing and manufacturing pharmaceutical products.
More about Organon and Co 's Market Share
|
Puma Biotechnology Inc
Share Performance
+22.87%
This Quarter
|
Puma Biotechnology Inc
Profile
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
More about Puma Biotechnology Inc 's Market Share
|
Cassava Sciences Inc
Share Performance
0.00%
Over The Past 5 Days
|
Cassava Sciences Inc
Profile
Cassava Sciences Inc is a pharmaceutical company that focuses on developing and commercializing novel drugs for neurological diseases. Their business model revolves around researching and developing innovative therapeutic solutions, conducting clinical trials to assess the effectiveness of their drugs, and ultimately marketing and selling their approved products to healthcare providers and patients. By strategically investing in the development of drugs for neurological disorders, Cassava Sciences aims to address unmet medical needs and potentially generate revenue through drug sales.
More about Cassava Sciences Inc's Market Share
|
Sanofi
Share Performance
+1.33%
This Year
|
Sanofi
Profile
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
More about Sanofi's Market Share
|
Takeda Pharmaceutical Company Limited
Share Performance
-1.69%
30 Days
|
Takeda Pharmaceutical Company Limited
Profile
Takeda Pharmaceutical Company Limited operates under a business model that primarily focuses on research, development, and commercialization of innovative pharmaceutical products. They collaborate with various stakeholders across the healthcare industry, including academia, biotechnology companies, and patient advocacy groups, to drive scientific advancements and understand patient needs. By leveraging their expertise, global presence, and strategic partnerships, Takeda aims to make a positive impact on patients' lives while ensuring long-term growth and sustainability.
More about Takeda Pharmaceutical Company Limited's Market Share
|
Teva Pharmaceutical Industries Limited
Share Performance
0.00%
Over The Past 5 Days
|
Teva Pharmaceutical Industries Limited
Profile
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.
More about Teva Pharmaceutical Industries Limited's Market Share
|
Therapeuticsmd Inc
Share Performance
-22.29%
This Year
|
Therapeuticsmd Inc
Profile
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
More about Therapeuticsmd Inc's Market Share
|
Viatris Inc
Share Performance
0.00%
Over The Past 5 Days
|
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
More about Viatris Inc 's Market Share
|
Sources: Unicycive Therapeutics Inc and all companies mentioned above in this report
|
